Diabetes

PRINCETON, N.J. — Novo Nordisk has appointed Curtis Oltmans as its corporate VP and general counsel for legal and quality affairs, the company said Friday.

In the new role, for which he will also join the company's U.S. executive team, Oltmans will be handle issues like law, quality, intellectual property, grants and philanthropy for the Danish drug maker's North American business.

NEW YORK — Target has launched new products and a co-pay assistance program for customers with diabetes, the mass merchandise retailer said.

Target announced the release of new blood glucose meters and test strips. The retailer also offers products like alternative site lancets, alcohol prep pads and diabetic nutritional shakes.

The company also announced the launch of a $4 co-pay assistance program, as well as a free private-label blood glucose meter for customers who qualify for the program.

CINCINNATI — Diabetes patients at Kroger pharmacies who have private insurance can pay $4 for blood-glucose test strips, the supermarket operator said.

Kroger said insured patients could pay a $4 co-pay for Kroger Premium test strips. People with diabetes can spend as much as $1,000 per year out of pocket on test strips alone, Kroger said.

RARITAN, N.J. — A subsidiary of Johnson & Johnson is seeking regulatory approval for a new Type 2 diabetes drug.

J&J division Janssen Research & Development announced Wednesday that it had filed with the Food and Drug Administration for a drug combining the experimental drug canagliflozin and immediate-release metformin, a common generic drug for diabetes.

The company also submitted a regulatory approval application to the FDA for canagliflozin in May 2012.

BAGSVÆRD, Denmark — Drug maker Novo Nordisk is creating what it calls the world's first all-diabetes professional cycling team, the company said.

The Danish pharmaceutical manufacturer announced plans to create Team Novo Nordisk, a global team with more than 100 cyclists, triathletes and runners, all of whom have diabetes.

NEW YORK — Women with ovarian cancer and diabetes who took the generic diabetes drug metformin showed better survival rates than those who did not take the drug, according to a new study led by the Mayo Clinic.

The study, published in the journal Cancer, enrolled 61 patients who took metformin and 178 who didn't. Of those who took the drug, 67% were surviving after five years, compared with 47% of those who didn't take it. Further analysis indicated that patients taking metformin were almost four times likelier to survive than those not taking it.

DALLAS — Personal care company Naterra has announced the national launch of Phase+, a skin care line designed to address the cosmetic effects that diabetes has on the skin. 

Phase+, which is now available at all Walgreens stores, is infused with anti-microbial ingredients to help prevent such skin care problems as cracked heels and ultra-dry skin from becoming a larger problem for diabetics, the company stated.    

Use of electronic health records 
improves medical outcomes among patients with diabetes, according to a recent study conducted by Kaiser Permanente.